Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809272344> ?p ?o ?g. }
- W2809272344 endingPage "28783" @default.
- W2809272344 startingPage "28772" @default.
- W2809272344 abstract "// Sebastian Regnery 1, 2 , Sebastian Adeberg 3 , Constantin Dreher 2 , Johanna Oberhollenzer 2 , Jan-Eric Meissner 4 , Steffen Goerke 4 , Johannes Windschuh 4 , Katerina Deike-Hofmann 2 , Sebastian Bickelhaupt 2 , Moritz Zaiss 5 , Alexander Radbruch 2 , Martin Bendszus 6 , Wolfgang Wick 7 , Andreas Unterberg 8 , Stefan Rieken 1 , Jürgen Debus 1 , Peter Bachert 4 , Mark Ladd 4, 9, 10 , Heinz-Peter Schlemmer 2 and Daniel Paech 2 1 Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany 2 German Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany 3 German Cancer Research Center (DKFZ), HIRO (Heidelberg Institute for Radiation Oncology), Heidelberg, Germany 4 German Cancer Research Center (DKFZ), Division of Medical Physics in Radiology, Heidelberg, Germany 5 Max-Planck-Institute, Tübingen, Germany 6 Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany 7 Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany 8 Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany 9 Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany 10 Faculty of Medicine, University of Heidelberg, Heidelberg, Germany Correspondence to: Daniel Paech, email: d.paech@dkfz.de Keywords: magnetic resonance imaging; amide-proton-transfer-imaging; nuclear overhauser imaging; glioblastoma; predictive biomarker Received: March 29, 2018 Accepted: May 24, 2018 Published: June 19, 2018 ABSTRACT Purpose: To prospectively investigate chemical exchange saturation transfer (CEST) MRI in glioblastoma patients as predictor of early tumor progression after first-line treatment. Experimental Design: Twenty previously untreated glioblastoma patients underwent CEST MRI employing a 7T whole-body scanner. Nuclear Overhauser effect (NOE) as well as amide proton transfer (APT) CEST signals were isolated using Lorentzian difference (LD) analysis and relaxation compensated by the apparent exchange-dependent relaxation rate (AREX) evaluation. Additionally, NOE-weighted asymmetric magnetic transfer ratio (MTRasym) and downfield-NOE-suppressed APT (dns-APT) were calculated. Patient response to consecutive treatment was determined according to the RANO criteria. Mean signal intensities of each contrast in the whole tumor area were compared between early-progressive and stable disease. Results: Pre-treatment tumor signal intensity differed significantly regarding responsiveness to first-line therapy in NOE-LD ( p = 0.0001), NOE-weighted MTRasym ( p = 0.0186) and dns-APT ( p = 0.0328) contrasts. Hence, significant prediction of early progression was possible employing NOE-LD (AUC = 0.98, p = 0.0005), NOE-weighted MTRasym (AUC = 0.83, p = 0.0166) and dns-APT (AUC = 0.80, p = 0.0318). The NOE-LD provided the highest sensitivity (91%) and specificity (100%). Conclusions: CEST derived contrasts, particularly NOE-weighted imaging and dns-APT, yielded significant predictors of early progression after fist-line therapy in glioblastoma. Therefore, CEST MRI might be considered as non-invasive tool for customization of treatment in the future." @default.
- W2809272344 created "2018-06-29" @default.
- W2809272344 creator A5005295293 @default.
- W2809272344 creator A5014073957 @default.
- W2809272344 creator A5016801239 @default.
- W2809272344 creator A5019876508 @default.
- W2809272344 creator A5020476636 @default.
- W2809272344 creator A5031718687 @default.
- W2809272344 creator A5037076463 @default.
- W2809272344 creator A5046483118 @default.
- W2809272344 creator A5054149506 @default.
- W2809272344 creator A5061901170 @default.
- W2809272344 creator A5067481396 @default.
- W2809272344 creator A5069571658 @default.
- W2809272344 creator A5073232336 @default.
- W2809272344 creator A5076635156 @default.
- W2809272344 creator A5079460128 @default.
- W2809272344 creator A5080482957 @default.
- W2809272344 creator A5080547151 @default.
- W2809272344 creator A5084473005 @default.
- W2809272344 creator A5084936317 @default.
- W2809272344 creator A5087579366 @default.
- W2809272344 date "2018-06-19" @default.
- W2809272344 modified "2023-10-18" @default.
- W2809272344 title "Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients" @default.
- W2809272344 cites W1482675544 @default.
- W2809272344 cites W1535417994 @default.
- W2809272344 cites W1817986201 @default.
- W2809272344 cites W1911361012 @default.
- W2809272344 cites W1923343538 @default.
- W2809272344 cites W1947637899 @default.
- W2809272344 cites W1969935384 @default.
- W2809272344 cites W1970855001 @default.
- W2809272344 cites W1995721991 @default.
- W2809272344 cites W2003126239 @default.
- W2809272344 cites W2006617902 @default.
- W2809272344 cites W2011106869 @default.
- W2809272344 cites W2013816626 @default.
- W2809272344 cites W2025919969 @default.
- W2809272344 cites W2027568261 @default.
- W2809272344 cites W2029961217 @default.
- W2809272344 cites W2035021866 @default.
- W2809272344 cites W2038552033 @default.
- W2809272344 cites W2070231190 @default.
- W2809272344 cites W2072418533 @default.
- W2809272344 cites W2092030031 @default.
- W2809272344 cites W2096287682 @default.
- W2809272344 cites W2104958914 @default.
- W2809272344 cites W2105100844 @default.
- W2809272344 cites W2106643634 @default.
- W2809272344 cites W2107731988 @default.
- W2809272344 cites W2118311655 @default.
- W2809272344 cites W2118887086 @default.
- W2809272344 cites W2130901509 @default.
- W2809272344 cites W2146110285 @default.
- W2809272344 cites W2148977460 @default.
- W2809272344 cites W2154526619 @default.
- W2809272344 cites W2154657194 @default.
- W2809272344 cites W2158681922 @default.
- W2809272344 cites W2162643152 @default.
- W2809272344 cites W2165871546 @default.
- W2809272344 cites W2253210936 @default.
- W2809272344 cites W2255398401 @default.
- W2809272344 cites W2261407128 @default.
- W2809272344 cites W2275616954 @default.
- W2809272344 cites W2307673977 @default.
- W2809272344 cites W2365629726 @default.
- W2809272344 cites W2529237571 @default.
- W2809272344 cites W2551389668 @default.
- W2809272344 cites W2573357968 @default.
- W2809272344 cites W2663608350 @default.
- W2809272344 cites W2734807975 @default.
- W2809272344 cites W2774805823 @default.
- W2809272344 cites W2783331044 @default.
- W2809272344 cites W2793328357 @default.
- W2809272344 cites W2799619016 @default.
- W2809272344 cites W4230172521 @default.
- W2809272344 doi "https://doi.org/10.18632/oncotarget.25594" @default.
- W2809272344 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6033360" @default.
- W2809272344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29983895" @default.
- W2809272344 hasPublicationYear "2018" @default.
- W2809272344 type Work @default.
- W2809272344 sameAs 2809272344 @default.
- W2809272344 citedByCount "55" @default.
- W2809272344 countsByYear W28092723442019 @default.
- W2809272344 countsByYear W28092723442020 @default.
- W2809272344 countsByYear W28092723442021 @default.
- W2809272344 countsByYear W28092723442022 @default.
- W2809272344 countsByYear W28092723442023 @default.
- W2809272344 crossrefType "journal-article" @default.
- W2809272344 hasAuthorship W2809272344A5005295293 @default.
- W2809272344 hasAuthorship W2809272344A5014073957 @default.
- W2809272344 hasAuthorship W2809272344A5016801239 @default.
- W2809272344 hasAuthorship W2809272344A5019876508 @default.
- W2809272344 hasAuthorship W2809272344A5020476636 @default.
- W2809272344 hasAuthorship W2809272344A5031718687 @default.
- W2809272344 hasAuthorship W2809272344A5037076463 @default.
- W2809272344 hasAuthorship W2809272344A5046483118 @default.